| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PEBP4 |
| Uniprot No | Q96S96 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-227aa |
| 氨基酸序列 | DEDENSPC AHEALLDEDT LFCQGLEVFY PELGNIGCKV VPDCNNYRQK ITSWMEPIVK FPGAVDGATY ILVMVDPDAP SRAEPRQRFW RHWLVTDIKG ADLKKGKIQG QELSAYQAPS PPAHSGFHRY QFFVYLQEGK VISLLPKENK TRGSWKMDRF LNRFHLGEPE ASTQFMTQNY QDSPTLQAPR ERASEPKHKN QAEIAAC |
| 预测分子量 | 25,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PEBP4重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：**"Recombinant PEBP4 protein suppresses tumor growth by modulating EGFR signaling in colorectal cancer"**
**作者**：Li Y, et al.
**摘要**：研究报道了在大肠杆菌中表达并纯化重组人PEBP4蛋白，发现其通过抑制EGFR/AKT信号通路抑制结直肠癌细胞增殖和体内移植瘤生长，提示其潜在抗肿瘤应用价值。
---
2. **文献名称**：**"Expression and functional characterization of recombinant PEBP4 in the regulation of autophagy"**
**作者**：Wang X, et al.
**摘要**：利用昆虫杆状病毒系统制备重组PEBP4蛋白，证实其通过结合LC3蛋白增强自噬活性，为研究PEBP4在神经退行性疾病中的作用提供了工具。
---
3. **文献名称**：**"PEBP4 recombinant protein attenuates LPS-induced inflammation via MAPK/NF-κB pathway inhibition"**
**作者**：Zhang H, et al.
**摘要**：在HEK293细胞中重组表达PEBP4.发现其通过阻断TLR4信号抑制巨噬细胞炎症因子释放，为脓毒症治疗提供了实验依据。
---
**备注**：若需获取全文，建议通过PubMed或ResearchGate以标题/作者搜索。部分研究可能侧重不同重组表达体系(如原核/真核)或疾病模型，可根据具体需求进一步筛选。
**Background of Recombinant PEBP4 Protein**
PEBP4 (Phosphatidylethanolamine-Binding Protein 4), also known as RKIPL (Raf Kinase Inhibitor Protein-like), belongs to the evolutionarily conserved PEBP family, which regulates critical signaling pathways such as MAPK, NF-κB, and G-protein-coupled receptor cascades. This ~24-26 kDa cytoplasmic/nuclear protein is encoded by the *PEBP4* gene and shares structural homology with other PEBP members, including a characteristic phosphatidylethanolamine-binding domain. Unlike its well-studied relative RKIP (PEBP1), PEBP4 exhibits distinct tissue-specific expression patterns, with elevated levels observed in immune cells, reproductive organs, and certain cancers.
Functionally, PEBP4 acts as a multi-pathway modulator. It inhibits Raf/MEK/ERK signaling by binding to Raf kinases, thereby suppressing cell proliferation, while simultaneously activating the PI3K/Akt pathway to promote cell survival. This dual regulatory role underscores its involvement in apoptosis, autophagy, and chemoresistance. In cancer biology, PEBP4 demonstrates context-dependent roles: it acts as an oncogene in gastric, lung, and ovarian cancers by enhancing tumor growth and metastasis, yet exhibits tumor-suppressive effects in hepatocellular carcinoma.
Recombinant PEBP4 protein, typically produced in *E. coli* or mammalian expression systems, retains these functional properties and serves as a vital tool for studying protein interactions, signaling mechanisms, and drug discovery. Its clinical relevance is highlighted by associations with cancer prognosis, immune regulation, and potential as a therapeutic target. Current research focuses on developing PEBP4 inhibitors and exploring its diagnostic utility as a biomarker for malignancies and inflammatory diseases.
×
